Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Jan 15, 2010

Premium

Protagen this week announced the addition of two members to its executive board and one member to its supervisory board.

Joining the executive board are Peter Schulz-Knappe and Martin Blüggel. Schulz-Knappe will take on operational responsibility for the company's diagnostics business unit. He is the former chief scientific officer at Proteome Sciences.

Blüggel will manage the Business Unit Protein Services. He is a co-founder of Protagen and is the chief operating officer.

Thomas Schweins joined the supervisory board. He is a member of the executive committee at Qiagen, where he is also vice president of marketing and strategy.


SDI said this week that Klaus Lindpaintner is joining the firm as chief scientific officer, effective Feb. 1.

Lindpaintner had been with F. Hoffman-La Roche, most recently as director of the Roche Molecular Medicine Laboratories and as Roche's global head of Molecular Medicines Policy and External Affairs, where he coordinated biomarker research based on proteomics, genomics, genetics, and associated disciplines from early discovery to late-stage clinical trials.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.